Loading data for TPST — first visit, this takes a few seconds.
Tempest Therapeutics Inc. (TPST)
NasdaqCM: TPST
· 실시간 가격 · USD
1.13
+0.12 (11.88%)
종가 기준: Aug 19, 2026, 1:30 PM
Tempest Therapeutics Inc. (TPST) Stock Price, Analysis & Data
11.88% (1D)
데이터 없음
TPST 소개
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and...
전체 기업 정보재무 실적
2025년 Tempest Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -26.26M로, -37.24% 감소했습니다.
재무제표어닝 서프라이즈
Tempest Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:
